The Latest Cardiac and Vascular News
Camzyos is the first and only FDA-approved cardiac myosin inhibitor that specifically targets the source of obstructive HCM Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo PRINCETON, N.J.–(BUSINESS WIRE)–Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) […]
ANDOVER, Mass., April 28, 2022 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval (PMA) of its OCS™ Heart System for […]
First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., Abbott’s steerable sheath offers precise and flexible placement when used with the company’s Amplatzer Amulet LAA Occluder […]
A first-of-its-kind study comparing image-guided ventricular tachycardia (VT) ablation to conventional, catheter-based strategies to evaluate efficiency and efficacy of image-guided procedures in cardiac arrythmia patients. CAMBRIDGE, Mass. and PESSAC, France, April 28, 2022 /PRNewswire/ — inHEART Inc., a privately-held medical device company delivering the world’s most sophisticated, AI-enabled, digitally-rendered 3D models of the heart, announced […]
Report demonstrates objective improvements in patients suffering from microvascular dysfunction VANCOUVER and MINNEAPOLIS, April 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the European Heart Journal has published an article entitled, “Impact of the Coronary Sinus Reducer on Absolute Blood Flow and Microvascular Resistance Case Report.” […]
New Addition to CareDx HeartCare Multimodality Portfolio Can Enable More Precise, Personalized Patient Care SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, […]
GUARDIAN Registry data presented at ISHLT 2022 has shown a 72% reduction (p=0.005) in Severe PGD (primary graft dysfunction) and a 39% reduction (p=0.03) in Mechanical Circulatory Support, in addition to improvement in 1-year survival1,2 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Paragonix Technologies, Inc., a leading organ preservation provider, announces today groundbreaking research from […]
Sunnybrook’s Schulich Heart Program to provide the latest innovative hybrid imaging of coronary arteries for complex cases TORONTO–(BUSINESS WIRE)–Conavi Medical Inc. (www.conavi.com), a leader of hybrid imaging guidance for common minimally invasive heart procedures, and Sunnybrook Health Sciences Centre, today announced that the Novasight Hybrid System is now being used […]
Studies Showed Sustained Reduction in LDL-C With no new Safety Findings The Combined Studies Evaluated Safety and Tolerability of Repatha in More Than 6,600 Patients for Over Five Years After Completing the Phase 3 FOURIER Trial Repatha is the Longest Studied PCSK9i THOUSAND OAKS, Calif., April 27, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) […]
BOSTON, April 27, 2022 /PRNewswire/ — The International Society for Heart and Lung Transplantation (ISHLT) has established a new sister organization: the ISHLT Foundation. This new entity serves as the charitable arm of ISHLT, and will fund a global portfolio of research grants and fellowship awards to improve patient care for advanced heart […]
